|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2003-3-24
|
|
pubmed:abstractText |
The acquisition of additional cytogenetic changes (clonal evolution, CE) during treatment of chronic myeloid leukemia (CML) with imatinib mesylate is currently regarded as an index of increasing resistance to imatinib. Therefore, to investigate whether CE as an isolated event increases the risk of disease progression during imatinib treatment, we compared the outcome of patients with CML in chronic phase (CML-CP) who developed CE whilst in complete hematologic remission with the outcome of comparable patients in complete hematologic remission who showed no evidence of CE.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0390-6078
|
|
pubmed:author |
pubmed-author:ApperleyJane FJF,
pubmed-author:BuaMarcoM,
pubmed-author:DazziFrancescoF,
pubmed-author:De MeloValeria A SVA,
pubmed-author:FootNicolaN,
pubmed-author:GoldmanJohn MJM,
pubmed-author:KaradimitrisAnastasiosA,
pubmed-author:KotzampaltirisPaulP,
pubmed-author:MarinDavidD,
pubmed-author:MarktelSarahS,
pubmed-author:OlavarriaEduardoE,
pubmed-author:RahemtullaAminA,
pubmed-author:SzydloRichardR
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
88
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
260-7
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12651263-Adolescent,
pubmed-meshheading:12651263-Adult,
pubmed-meshheading:12651263-Aged,
pubmed-meshheading:12651263-Chromosome Aberrations,
pubmed-meshheading:12651263-Clone Cells,
pubmed-meshheading:12651263-Cytogenetic Analysis,
pubmed-meshheading:12651263-Disease Progression,
pubmed-meshheading:12651263-Drug Resistance, Neoplasm,
pubmed-meshheading:12651263-Female,
pubmed-meshheading:12651263-Fusion Proteins, bcr-abl,
pubmed-meshheading:12651263-Humans,
pubmed-meshheading:12651263-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:12651263-Male,
pubmed-meshheading:12651263-Middle Aged,
pubmed-meshheading:12651263-Piperazines,
pubmed-meshheading:12651263-Prognosis,
pubmed-meshheading:12651263-Pyrimidines
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression.
|
|
pubmed:affiliation |
Department of Hematology, Imperial College at Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
